These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 21220306)

  • 41. Activation of mitogen-activated protein kinase signaling and development of papillary thyroid carcinoma in thyroid-stimulating hormone receptor D633H knockin mice.
    Eszlinger M; Stephenson A; Mirhadi S; Patyra K; Moran MF; Khalil M; Kero J; Paschke R
    Eur Thyroid J; 2023 Dec; 12(6):. PubMed ID: 37855416
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
    Crescenzi A; Guidobaldi L; Nasrollah N; Taccogna S; Cicciarella Modica DD; Turrini L; Nigri G; Romanelli F; Valabrega S; Giovanella L; Onetti Muda A; Trimboli P
    Horm Metab Res; 2014 May; 46(5):370-4. PubMed ID: 24570209
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acceleration of BRAF
    Shimamura M; Kurashige T; Kuatov R; Nakashima M; Nagayama Y
    Endocrine; 2020 Sep; 69(3):571-577. PubMed ID: 32281047
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thyrotropin, but Not Thyroid-Stimulating Antibodies, Induces Biphasic Regulation of Gene Expression in Human Thyrocytes.
    Jang D; Morgan SJ; Klubo-Gwiezdzinska J; Banga JP; Neumann S; Gershengorn MC
    Thyroid; 2020 Feb; 30(2):270-276. PubMed ID: 31805824
    [No Abstract]   [Full Text] [Related]  

  • 47. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.
    Bommarito A; Richiusa P; Carissimi E; Pizzolanti G; Rodolico V; Zito G; Criscimanna A; Di Blasi F; Pitrone M; Zerilli M; Amato MC; Spinelli G; Carina V; Modica G; Latteri MA; Galluzzo A; Giordano C
    Endocr Relat Cancer; 2011 Dec; 18(6):669-85. PubMed ID: 21903858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CYP2S1 is a synthetic lethal target in BRAF
    Li Y; Su X; Feng C; Liu S; Guan H; Sun Y; He N; Ji M; Hou P
    Signal Transduct Target Ther; 2020 Sep; 5(1):191. PubMed ID: 32913191
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma.
    Romitti M; Wajner SM; Ceolin L; Ferreira CV; Ribeiro RV; Rohenkohl HC; Weber Sde S; Lopez PL; Fuziwara CS; Kimura ET; Maia AL
    Endocr Relat Cancer; 2016 Mar; 23(3):135-46. PubMed ID: 26825960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.
    Rosignolo F; Maggisano V; Sponziello M; Celano M; Di Gioia CR; D'Agostino M; Giacomelli L; Verrienti A; Dima M; Pecce V; Durante C
    J Endocrinol Invest; 2015 Dec; 38(12):1283-9. PubMed ID: 26003825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Disruption of mutated BRAF signaling modulates thyroid cancer phenotype.
    Hanly EK; Rajoria S; Darzynkiewicz Z; Zhao H; Suriano R; Tuli N; George AL; Bednarczyk R; Shin EJ; Geliebter J; Tiwari RK
    BMC Res Notes; 2014 Mar; 7():187. PubMed ID: 24673746
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
    Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
    Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas.
    Gérard AC; Daumerie C; Mestdagh C; Gohy S; De Burbure C; Costagliola S; Miot F; Nollevaux MC; Denef JF; Rahier J; Franc B; De Vijlder JJ; Colin IM; Many MC
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4977-83. PubMed ID: 14557483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TSH signaling overcomes B-RafV600E-induced senescence in papillary thyroid carcinogenesis through regulation of DUSP6.
    Kim YH; Choi YW; Han JH; Lee J; Soh EY; Park SH; Kim JH; Park TJ
    Neoplasia; 2014 Dec; 16(12):1107-20. PubMed ID: 25499223
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
    He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
    Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues.
    Kim SW; Kim HK; Lee JI; Jang HW; Choe JH; Kim JH; Kim JS; Hur KY; Kim JH; Chung JH
    Endocr Res; 2013; 38(2):89-97. PubMed ID: 23544999
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
    Gao WL; Wie LL; Chao YG; Wie L; Song TL
    Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BRAF
    Traversi F; Stooss A; Dettmer MS; Charles RP
    Thyroid; 2021 May; 31(5):787-799. PubMed ID: 33012268
    [No Abstract]   [Full Text] [Related]  

  • 59. Expression Profiling of a Human Thyroid Cell Line Stably Expressing the BRAFV600E Mutation.
    Kim BA; Jee HG; Yi JW; Kim SJ; Chai YJ; Choi JY; Lee KE
    Cancer Genomics Proteomics; 2017 Jan; 14(1):53-67. PubMed ID: 28031237
    [TBL] [Abstract][Full Text] [Related]  

  • 60. (V600E)BRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a Snail-dependent mechanism.
    Baquero P; Sánchez-Hernández I; Jiménez-Mora E; Orgaz JL; Jiménez B; Chiloeches A
    Cancer Lett; 2013 Jul; 335(1):232-41. PubMed ID: 23435375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.